Lobe Sciences to Attend ArcStone-Kingswood Growth Summit in Toronto

Lobe Sciences, a clinical-stage biotechnology company, is set to participate in the 3rd Annual ArcStone-Kingswood Growth Summit in Toronto on September 16, 2026. The summit, held at the Sheraton Center Toronto Hotel, will bring together growth issuers and a curated group of investors, family offices, institutional investors, capital market professionals, and service providers for a full day of company presentations, networking, and one-on-one meetings.

Dr. David Kideckel, Ph.D., MBA, Chief Financial Officer of Lobe Sciences, will represent the company at the summit. His participation is aimed at introducing Lobe Sciences to Canadian and U.S. investors. The company is advancing innovative therapies for neurological and rare diseases, with its lead CNS asset, L-130 (Conjugated Psilocin®), a patented compound engineered to produce consistent, controllable psilocin exposure. L-130 is being developed initially for cluster headache, with co-development programs underway for PTSD, substance use disorder, generalized anxiety disorder, and other neuropsychiatric disorders.

Unlike conventional psilocybin, which produces highly variable psilocin exposure between patients, L-130 is designed to deliver psilocin directly with a predictable pharmacokinetic profile. The Company's development strategy is built on the premise that the therapeutic benefits of psilocin may be achieved at controlled exposure levels below those typically associated with hallucinations, potentially separating efficacy from the psychedelic experience and substantially expanding the clinical and commercial potential of psychedelic-derived medicines.

Additionally, Lobe Sciences is advancing S-100, a novel therapeutic for sickle cell disease, with Phase 3 clinical development anticipated to commence in mid-2027. Dr. Kideckel expressed enthusiasm about the opportunity to discuss these programs with investors at the summit, stating, "This is a valuable opportunity to introduce Lobe Sciences to Canadian and U.S. investors. We are advancing innovative therapies for neurological and rare diseases, and I look forward to meeting investors in Toronto to discuss how we intend to advance these programs."

The ArcStone-Kingswood Growth Summit will feature a curated program of one-on-one meetings connecting investors with appropriate projects, as well as keynote presentations, panel discussions, and conversations on industry developments. The event is designed to foster connections and provide a platform for growth issuers to present their projects to a targeted audience of investors and professionals.

Lobe Sciences Ltd. is a clinical-stage biotechnology company focused on advancing innovative therapies for neurological and rare diseases. Its lead asset, L-130, is a patented new chemical entity initially being developed for cluster headache, with co-development programs underway for various neuropsychiatric disorders. The company is also developing S-100, a novel therapeutic for sickle cell disease, with Phase 3 clinical development anticipated to begin in mid-2027.